Results 151 to 160 of about 50,558 (217)

A randomized controlled Phase I de-escalation trial of molnupiravir and nirmatrelvir/ritonavir combination for mild-moderate SARS-CoV-2 infection. [PDF]

J Antimicrob Chemother
Khoo SH, FitzGerald R, Edwards CJ, Ahmad S, Saunders G, Else LJ, Shaw V, Mozgunov P, Northey J, Dickinson L, Knox E, Buadi A, Hale C, Reynolds HE, Middleton C, Bullock K, Walker L, Walker L, Tetlow M, Lyon R, Gibney J, Amara A, Greenhalf W, Burdon A, Dixon J, Jaki T, Chiong J, Lalloo DG, Owen A, Jacobs M, Fletcher T, Griffiths G, AGILE CST-8 study group .   +32 more
europepmc   +1 more source

Evidence-to-Recommendation Framework for 2026 ACE Clinical Guideline on upper respiratory tract infections - rational antimicrobial use. [PDF]

Singapore Med J
Lim B, Chua SC, Xu R, Ricci V, Kim PA, Expert Group for URTI ACG.   +5 more
europepmc   +1 more source

Primary care physicians' perspectives on managing mild-to-moderate COVID-19 in populations at risk for progression to severe disease: a survey-based study. [PDF]

BMC Prim Care
Kasher C, Distelman-Menachem T, Bareket-Samish A, Shapiro Ben David S.   +3 more
europepmc   +1 more source

QT interval prolongation and its related factors before and after receiving lopinavir-ritonavir in the COVID-19 era: a historical cohort study. [PDF]

Virus Res
Jangjou A, Izadpanah P, Moqhadas M, Faramarzi H, Fahimi MH, Ghazipoor H, Hamrah H, Kamyab H.   +7 more
europepmc   +1 more source

Longitudinal Clinical and Molecular Characterization of a Single Pediatric Case of Vertically Acquired HIV-1 Subtype C with Baseline Resistance to Protease Inhibitors. [PDF]

Microorganisms
Zaher KA, El-Daly MM, Zaki EA, Alhazmi MM, Abdulhaq A, El-Kafrawy SA, Azhar EI.   +6 more
europepmc   +1 more source

Physiologically Based Pharmacokinetic Modeling to Assess Antiretroviral-BTK Inhibitor Interactions and Provide Recommendations for Co-Administration Regimens. [PDF]

Pharmaceutics
Chen L, Wang X, Li L, Yang Y, Liu Y, Chen W.   +5 more
europepmc   +1 more source

A study on the stability of ritonavir form III processed in orbit and returned to Earth. [PDF]

NPJ Microgravity
Bauser HC, Smith PA, Parent SD, Chan LR, Bhavsar AS, Condon KH, McCalip A, Croom JM, Purcell DK, Bogdanowich-Knipp SJ, Smith DT, Cowans BA, Alajlouni R, Byrn SR, Radocea A.   +14 more
europepmc   +1 more source

Breastmilk transfer and infant exposure to atazanavir/ritonavir in breastfeeding women with HIV: results from IMPAACT 2026. [PDF]

Front Reprod Health
Barr EA, Pinilla M, Momper JD, Eke AC, Koech L, Brooks KM, Ndyanabangi V, Burchett SK, Valiyaparambil S, Mirochnick M, Stek AM, Best BM, Jeffrey R, Stotz C, Van Schalkwyk M, Browning R, Shapiro DE, Powis KM.   +17 more
europepmc   +1 more source

Early outcomes of South African children with persistent viral non-suppression following switch to dolutegravir-based antiretroviral therapy. [PDF]

South Afr J HIV Med
Guerrini M, Maré M, Hulsman C, Greybe L, Lishman J, Edson C, Hisham T, Frigati L, Rabie H.   +8 more
europepmc   +1 more source

Occult hepatitis B and risk of reactivation following switch to non-hepatitis B virus-active antiretroviral therapy in people with HIV. [PDF]

AIDS
Lapadula G, Soria A, Puoti M, Bonfanti P.   +3 more
europepmc   +1 more source